Fluidigm: Ana Stankovic
Fluidigm has appointed Ana Stankovic to its board of directors. Stankovic is currently managing partner at Koliada Consulting, a firm focused on biotech, medical devices, and in vitro diagnostics. Previously, she was senior vice president for worldwide regional medical affairs and global health at Becton Dickinson. She served in senior roles at BD for more than a decade, leading medical affairs and clincal operations for various BD units. Prior to this, Stankovic was an associate clinical professor in the Department of Pathology, Microbiology, and Immunology at Vanderbilt University School of Medicine. She also served for two years as a guest lecturer in the Department of Pathology at Harvard Medical School, and is a former chief resident in the Department of Pathology at the University of Alabama at Birmingham.
Danaher: Jennifer Honeycutt
Danaher announced it has appointed Jennifer Honeycutt as executive VP, responsible for Beckman Coulter Life Sciences, Integrated DNA Technologies, Leica Microsystems, Molecular Devices, Pall, Phenomenex, and Sciex. Previously, Honeycutt was a VP and group executive overseeing Pall, IDT, and the Danaher Life Sciences platform in China, as well as the president of Pall. From 2013 to 2016, she was president of Beckman Coulter Life Sciences. She joined Danaher in 1999 and served in general management roles at Hach Ultra Analytics, Anderson Instrument Company, and Linx Printing Technologies.
Guardant Health: Michael Bell
Guardant Health has named Michael Bell as CFO effective Jan. 4, 2021. He replaces Derek Bertocci who is retiring. Bell has more than 25 years of international finance and accounting experience and has worked in clinical diagnostics, pharma, and public accounting. He was most recently CFO of CareDx and was formerly CFO for Metabiota, Singulex, and Novartis Diagnostics.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.